{"prompt": "['Inadequate bone marrow function, defined by any of:', '- Absolute neutrophil count (ANC) < 1.5 X 10%/L', '-', 'Platelet count < 100 X 10%/L', '-', 'Haemoglobin < 9 g/dL', 'Impaired liver function, defined by any of:', \"- Serum (total) bilirubin > 1.25 X upper limit of normal (ULN). In case of Gilbert's\", 'syndrome: a total bilirubin of 2 X ULN is permitted.', '-', 'Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 1.25 X ULN', '- Albumin < 25 g/L', 'Inadequate renal function with serum creatinine > 1.5 X ULN', 'Current severe, uncontrolled systemic disease that may interfere with planned treatment', '(e.g., clinically significant cardiovascular, pulmonary, or metabolic disease; wound-', 'healing disorders)', 'Pregnant or breastfeeding, or intending to become pregnant during the study or within', 'seven months after the last dose of study treatment. Women of childbearing potential', 'must have a negative serum pregnancy test result within seven days prior to initiation of', 'study treatment', 'Any serious medical condition or abnormality in clinical laboratory tests that, in the', \"investigator's judgment, precludes the patient's safe participation in, and completion of,\", 'the study', 'Known active liver disease, for example, active viral hepatitis infection (i.e., hepatitis B or', 'hepatitis C), autoimmune hepatic disorders, or sclerosing cholangitis', 'Concurrent, serious, uncontrolled infections, or known infection with human', 'immunodeficiency virus (HIV)', 'Known hypersensitivity to any of the study drugs, excipients, and/or murine proteins', 'Current chronic daily treatment with corticosteroids (dose > 10 mg methylprednisolone or', 'equivalent excluding inhaled steroids)', '4.2', 'METHOD OF TREATMENT ASSIGNMENT', 'Eligible patients will be randomly allocated at study entry to either Arm A (P+H IV followed', 'by pertuzumab and trastuzumab FDC SC) or Arm B (pertuzumab and trastuzumab FDC SC', 'followed by P+H IV).', 'Randomization will occur via a web-based response system (IWRS) in a 1:1 ratio.', 'Randomization will be stratified according to neoadjuvant chemotherapy regimen', '(anthracyclines + taxanes vs. carboplatin + taxanes vs. taxanes only), neoadjuvant treatment', 'response (pCR vs. non-pCR), and hormone receptor status (positive [ER-positive and/or', 'PgR-positive) or negative [ER-negative and PgR-negative]).', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '45 / Protocol MO40628, Version 12']['4.3', 'STUDY TREATMENT', 'The IMPs for this study are pertuzumab and trastuzumab FDC SC (loading dose', 'configuration and maintenance dose configuration), Perjeta IV and Herceptin IV. All study', 'drugs will be provided by the Sponsor free of charge.', 'Study drug supplies will be labelled in accordance with applicable legal requirements and will', 'be printed in the local language. The storage conditions for each study drug will be', 'described on the medication label. Study drug supplies should not be used beyond the', 'expiration date provided by the manufacturer.', 'Please refer to the Pharmacy Manual for all instructions pertaining to study drug supply and', 'management.', '4.3.1', 'Study Treatment Formulation, Packaging, and Handling', '4.3.1.1', 'Pertuzumab and Trastuzumab FDC SC', 'A loading and maintenance dose of pertuzumab and trastuzumab FDC SC will be provided', 'in the following configurations as single vials:', 'Loading dose: a sterile solution for injection containing L-histidine hydrochloride,', 'trehalose, sucrose, polysorbate 20, methionine, and rHuPH20 (2,000 U/mL). Each single', 'use 20 mL glass colourless vial contains 1200 mg of pertuzumab and 600 mg of', 'trastuzumab in 15 mL of solution.', 'Maintenance dose: a sterile solution for injection containing L-histidine hydrochloride,', 'trehalose, sucrose, polysorbate 20, methionine, and rHuPH20 (2,000 U/mL). Each single', 'use 15 mL colourless glass vial contains 600 mg of pertuzumab and 600 mg of', 'trastuzumab in 10 mL of solution.', 'For information on the packaging, handling and storage of pertuzumab and trastuzumab', \"FDC SC, see the Pharmacy Manual and Perjeta Investigator's Brochure.\", '4.3.1.2', 'Perjeta IV', 'Perjeta IV is provided as a sterile, preservative-free, single use formulation containing 30', 'mg/mL pertuzumab in 20 mM L-histidine acetate, 120 mM sucrose, and 0.02% (w/v)', 'polysorbate 20 at pH 6.0. Each 20 mL vial contains 420 mg of pertuzumab (14.0 mL/vial).', 'For information on the packaging, storage and dispensing of Perjeta IV, see the current', \"Perjeta Investigator's Brochure and Summary of Product Characteristics (SmPC).\", '4.3.1.3', 'Herceptin IV', 'Herceptin IV is provided in single or multi-dose freeze-dried preparations containing nominal', 'trastuzumab amounts of 150 mg/vial or 440 mg/vial, respectively. The drug is formulated in', 'histidine/histidine-HCI; a, -trehalose dehydrate; and polysorbate 20.', 'For information on the packaging, storage, and dispensing of Herceptin IV, see the current', \"Herceptin Investigator's Brochure and SmPC.\", '4.3.2', 'Study Treatment Dosage, Administration, and Compliance', 'The treatment regimens are summarized in Section 3.1 and below.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '46 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}